News stories about Minerva Neurosciences (NASDAQ:NERV) have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Minerva Neurosciences earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 47.6368032482121 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Shares of Minerva Neurosciences (NASDAQ:NERV) traded up $0.20 on Friday, reaching $5.40. 198,400 shares of the company were exchanged, compared to its average volume of 217,429. Minerva Neurosciences has a twelve month low of $4.80 and a twelve month high of $14.15.
Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.28) EPS for the quarter. During the same quarter last year, the business posted ($0.24) EPS. equities analysts forecast that Minerva Neurosciences will post -1.28 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This news story was reported by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.com-unik.info/2017/11/24/minerva-neurosciences-nerv-receiving-somewhat-positive-media-coverage-report-shows.html.
About Minerva Neurosciences
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
What are top analysts saying about Minerva Neurosciences Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Minerva Neurosciences Inc and related companies.